Covered recipient · General Payments record
BAMIDELE A EKUNSANMI
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$3,233.96
- Reported across 54 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,217.44 | 2 |
| Food and Beverage | $753.15 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $1,617.44 | 4 |
| ABBVIE INC. | $177.47 | 3 |
| Novo Nordisk AS | $61.82 | 4 |
| PFIZER INC. | $54.01 | 2 |
| Otsuka America Pharmaceutical, Inc. | $32.82 | 2 |
| Lucid Diagnostics Inc. | $27.03 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.40 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682415 | CMS |
| ABBVIE INC. | $123.38 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682417 | CMS |
| ABBVIE INC. | $27.69 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103682419 | CMS |
| Amgen Inc. | $125.00 | 01/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111568719 | CMS |
| Amgen Inc. | $275.00 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111568721 | CMS |
| Amgen Inc. | $562.74 | 02/23/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1111568723 | CMS |
| Amgen Inc. | $654.70 | 02/23/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1111568725 | CMS |
| Lucid Diagnostics Inc. | $27.03 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152301216 | CMS |
| Novo Nordisk Inc | $15.10 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096854087 | CMS |
| Novo Nordisk Inc | $16.80 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097730320 | CMS |
| Novo Nordisk Inc | $13.59 | 08/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096595162 | CMS |
| Novo Nordisk Inc | $16.33 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096635059 | CMS |
| Otsuka America Pharmaceutical, Inc. | $15.95 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118888353 | CMS |
| Otsuka America Pharmaceutical, Inc. | $16.87 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118888355 | CMS |
| PFIZER INC. | $27.98 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131601616 | CMS |
| PFIZER INC. | $26.03 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131601620 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.